Interstitial Lung Abnormalities in Renal Transplant Recipients (LCRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01017757|
Recruitment Status : Unknown
Verified November 2009 by University of Parma.
Recruitment status was: Active, not recruiting
First Posted : November 23, 2009
Last Update Posted : November 23, 2009
|Condition or disease||Intervention/treatment|
|Renal Transplantation Kidney-pancreas Transplantation||Procedure: High-resolution CT scanning|
Prospective, cross-sectional study examining the high-resolution CT scans obtained in 63 stable renal transplant recipients taking immunosuppressive treatment for at least 24 months. The findings in patients taking the newer immunosuppressive drugs (mycophenolic acid, sirolimus and everolimus) are compared with those of the patients treated in the traditional way (cyclosporine, tacrolimus, azathioprine). All patients undergo high-resolution CT scanning.
Eligibility criteria: recipients of kidney or kidney-pancreas transplant, on immunosuppressive therapy for at least 24 months, with stable renal function and absence of any overt lung disease or lung alterations induced by other drugs, systemic diseases or occupational exposure to fibrogenic agents.
|Study Type :||Observational|
|Actual Enrollment :||63 participants|
|Official Title:||Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan|
|Study Start Date :||June 2007|
|Primary Completion Date :||October 2007|
|Estimated Study Completion Date :||November 2009|
|Renal transplant patients||
Procedure: High-resolution CT scanning
High-resolution CT scanning
- Subclinical lung alterations as assessed by high-resolution CT scanning [ Time Frame: CT is performed at study entry and, if abnormalities are found, it is repeated at 3-6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01017757
|Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital|
|Parma, Italy, 43100|
|Principal Investigator:||Carlo Buzio, MD||University of Parma|